F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The FDA approved daraxonrasib on August 26, 2026, as a once-daily oral pill for patients with previously treated metastatic pancreatic cancer. Manufactured by Revolution Medicines, the first-in-class RAS inhibitor doubled median survival compared to chemotherapy in clinical trials. Experts expect the drug to transform the treatment of a disease long considered difficult to treat due to an undruggable gene.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA approved daraxonrasib on August 26, 2026.
- ✓ Daraxonrasib is a once-daily oral pill.
- ✓ The drug doubled median survival compared to chemotherapy in pancreatic cancer patients.
- ✓ Daraxonrasib is a first-in-class RAS inhibitor for metastatic pancreatic cancer.
What changed
The approval date is now confirmed as August 26, 2026, and the drug is identified as a once-daily oral pill branded as RASONQUE.
Live updates
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA approved daraxonrasib on August 26, 2026, as a once-daily oral pill for patients with previously treated metastatic pancreatic cancer. Manufactured by Revolution Medicines, the first-in-class RAS inhibitor doubled median survival compared to chemotherapy in clinical trials. Experts expect the drug to transform the treatment of a disease long considered difficult to treat due to an undruggable gene.
Why it matters
Metastatic pancreatic cancer has historically offered physicians and patients very few treatment options. This approval introduces a targeted therapy designed to inhibit the RAS gene.
What is confirmed
- The FDA approved daraxonrasib on August 26, 2026.
- Daraxonrasib is a once-daily oral pill.
- The drug doubled median survival compared to chemotherapy in pancreatic cancer patients.
- Daraxonrasib is a first-in-class RAS inhibitor for metastatic pancreatic cancer.
What to watch next
- Real-world efficacy data following widespread clinical adoption
- FDA decisions on expanding the drug for earlier stages of pancreatic cancer
confidence 100%Sources used for this update (5)
- www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
- www.yahoo.com — The Drug That Finally Cracked Pancreatic Cancer’s “Undruggable” Gene
- oncodaily.com — FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
- oncodaily.com — FDA Approves Daraxonrasib: Here is What Oncologists Have to Say
- medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The FDA has approved daraxonrasib, a drug manufactured by Revolution Medicines, for the treatment of previously treated metastatic pancreatic cancer. Clinical trial results showed the drug could nearly double life expectancy for pancreatic cancer patients. Daraxonrasib is a targeted therapy that has been hailed as a potential game-changer in the treatment of pancreatic cancer.
Why it matters
Pancreatic cancer is a deadly disease with limited treatment options. The approval of daraxonrasib offers new hope for patients with advanced pancreatic cancer. The drug's unique mechanism of action and promising clinical trial results make it a significant development in the field of oncology. Pancreatic cancer is one of the most lethal forms of cancer, with a five-year survival rate of around 12%.
What is confirmed
- The FDA has approved daraxonrasib for the treatment of previously treated metastatic pancreatic cancer.
- Daraxonrasib is manufactured by Revolution Medicines.
- Clinical trial results showed daraxonrasib could nearly double life expectancy for pancreatic cancer patients.
- Daraxonrasib is a targeted therapy.
What to watch next
- The impact of daraxonrasib on patient outcomes and survival rates.
- Potential side effects and safety concerns associated with daraxonrasib.
- The drug's availability and accessibility for patients with pancreatic cancer.
confidence 95%Sources used for this update (10)
- WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
- The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
- CNN — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- WCVB — FDA approves first-of-a-kind pancreatic cancer drug trialed in Boston
- CancerNetwork — FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
- Axios — A major RAS drug milestone could spur interest in rival assets
- Le Monde.fr — US approves new treatment for pancreatic cancer
- ABC News - Breaking News, Latest News and Videos — FDA approves breakthrough drug to treat advanced pancreatic cancer
- People.com — FDA Approves Groundbreaking Drug That Slows Pancreatic Cancer
- nypost.com — FDA approves ‘life-altering’ pancreatic cancer drug that nearly doubles life expectancy
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community